Simelgat Plus

Quick links to important sections

Simelgat Plus

Treatment option:

Medically reviewed

Rosario Oropesa

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Simelgat Plus

Property Description
Active Ingredients Magaldrate and Simethicone
Form Oral Suspension and Chewable Tablets
Pharmacological Class Antacid and Anti-flatulence Agent
General Purpose Dual relief for acidity and gas-related pressure
Origin Synthetic

Defining Simelgat Plus: What Type of Medicine is It?

Simelgat Plus is a fixed-dose combination product classified as a Gastrointestinal Agent, specifically comprising the roles of an Antacid and an Anti-flatulence Agent. This formulation is designed for multimodal therapy, simultaneously addressing chemical irritation and physical discomfort within the digestive tract. The Antacid component, Magaldrate, is recognized under the WHO ATC classification A02AD02.

This integrated approach combines these two agents to provide more comprehensive relief than single-component treatments. The product is frequently positioned for temporary digestive upset characterized by both burning sensations and pressure.

Composition and Forms: Magaldrate, Simethicone, and Delivery

Simelgat Plus contains two primary active ingredients of synthetic origin: Magaldrate (an aluminum and magnesium compound) and Simethicone (a silicone-based substance). Both components are formulated for Oral Administration and are typically available either as an oral suspension with an aqueous vehicle or in the physical form of chewable tablets.

Magaldrate functions via rapid acid neutralization, while Simethicone acts as a non-systemic surfactant, physically reducing the surface tension of gas bubbles. This dual-component mixture is distinguished in the pharmaceutical industry for its capability to address both acid and gas-related symptoms efficiently.

General Purpose: What is the Overall Benefit?

The overall purpose is to provide comprehensive relief by leveraging the synergistic effect of its two components: acid neutralization and anti-gas defoaming action. The dual action means the medication is fundamentally designed to alleviate the pressure and discomfort associated with trapped gas and the burning sensation stemming from excessive acidity. The combination is designed to reduce symptoms and, because both active ingredients primarily act within the gut with negligible systemic absorption, the medication is considered non-systemic in its primary effects.

What side effects are possible with Simelgat Plus?

Official Safety Profile of Simelgat Plus

Regulatory documents organize the safety information for Simelgat Plus into categories based on frequency and seriousness. The medicine is associated with a risk profile related to its immunosuppressive effects.

Very Common and Frequent Adverse Reactions

The most frequently reported adverse reactions, occurring in 1 out of 10 people or more (Very Common), include conditions such as high blood pressure (hypertension), elevated potassium levels (hyperkalaemia), high cholesterol (hypercholesterolaemia), headache, constipation, pain, nausea, peripheral swelling (oedema), and various signs of infection, such as urinary tract infection.

Serious Adverse Reactions

The most significant risks formally documented in regulatory labeling are related to the immune system. These include:

  • Severe Acute Hypersensitivity Reactions: Rare but serious allergic responses, which may be life-threatening (anaphylactoid-type reactions). These can occur upon first exposure or re-exposure.
  • Serious Infections: An increased risk of serious, opportunistic, or fatal infections, including sepsis, due to the drug’s immunosuppressive action.
  • Lymphoproliferative Disorders: A potential long-term risk of conditions such as lymphoma.

Safety-Related Restrictions and Considerations

The official safety information includes specific restrictions for use:

  • Pregnancy and Lactation: Simelgat Plus is formally contraindicated during pregnancy and breastfeeding.
  • Contraception: Women of childbearing potential are required to use effective contraception during treatment and for a specified period (up to 16 weeks) after receiving the last dose.
  • Discontinuation: The drug must be permanently discontinued if a severe hypersensitivity reaction occurs, and the second planned dose may be withheld in the event of severe post-operative complications.

Overdose and Emergency Response

Overdose and When to Seek Help

The official guidance from regulatory authorities mandates that any suspected overdose of Simelgat Plus requires immediate action. Users must seek immediate medical attention or contact a Poison Control Center without delay. This action is required because seemingly localized symptoms may mask the potential for severe systemic complications.

Acute overdosage commonly presents with gastrointestinal distress, including diarrhea, vomiting, severe constipation, and abdominal pain. Since the Simethicone component is non-absorbed, serious systemic symptoms are primarily related to the Antacid component, Magaldrate.

The most critical risk is Systemic Metal Ion Toxicity from the absorption of aluminum and magnesium. This can lead to severe outcomes such as Hypermagnesemia and Aluminum Intoxication. These toxicities carry a documented risk of developing Encephalopathy and Hypophosphatemia, particularly in patients with Renal Impairment.

Treatment focuses on supportive and symptomatic measures, such as rehydration. For severe metal ion accumulation, regulatory documents specify that advanced procedures like Haemodialysis may be necessary, underscoring the requirement for urgent hospital monitoring.

Therapeutic Uses of Simelgat Plus

What Simelgat Plus Treats: Main Uses and Benefits

Simelgat Plus is used for managing symptoms related to both acid and gas. As aligned with common therapeutic uses for its components, the medication is relevant for easing symptoms that interfere with daily functioning, primarily addressing two symptom domains. It is commonly used to help manage symptom clusters that may appear suddenly, specifically the burning sensations from acid alongside the physical discomfort from trapped gas bubbles.


Symptomatic Support for Acute Distress

This medication is applied across domains where additional symptomatic support is needed, such as managing the symptoms of Gastritis, Peptic Ulcers, and Gastroesophageal Reflux Disease (GERD). It is generally relevant for easing recurrent or episodic manifestations, such as postprandial distress or discomfort that becomes more disruptive during flare-ups.

It is applied during phases when symptoms become more prominent, offering supportive relief that helps maintain a sense of stability.


Symptom Focus: Relief for Dual Discomfort Simelgat Plus is commonly used when patients experience both heartburn and abdominal fullness, contributing to the management of these co-occurring symptoms.

Regulatory References

  1. NIH MedlinePlus Drug Information

Eligibility and Restrictions for Use

Official Eligibility for Simelgat Plus Use

The eligibility for Simelgat Plus is strictly defined by regulatory documents based on a patient's age, organ function, and physiological status.

Populations Strictly Contraindicated

The medicine must not be used by specific groups as mandated by official labeling:

  • Severe Renal Impairment: Individuals diagnosed with severe kidney disorders are prohibited from use. This restriction is due to the risk of accumulation of aluminum and magnesium ions, which can lead to toxicity.
  • Hypersensitivity: Patients with a known allergy or hypersensitivity to Magaldrate, Simethicone, or any excipient in the formulation are strictly contraindicated.

Age-Related Eligibility

  • Allowed Use: Simelgat Plus is permitted for use by Adults and Adolescents/Children aged 12 years and older.
  • Not Recommended: Use in children younger than 12 years is officially not recommended, as safety and efficacy have not been formally established by regulatory authorities for this younger age group.

Conditional and Restricted Use

  • Pregnancy and Lactation: Use during pregnancy or breastfeeding is placed under a restricted use status. It is only recommended when a healthcare provider determines the potential benefits outweigh the risks, due to limited controlled human data.
  • Moderate Renal Impairment: Patients with less severe kidney impairment must use the medicine under medical supervision and with caution.
  • Prolonged Use: Use exceeding the labeled duration is restricted, especially due to the potential for impacting phosphate levels with long-term aluminum exposure.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Simelgat Plus contains Simeticone, a non-systemic agent that acts locally in the gastrointestinal tract. Due to its mechanism of action, Simeticone can physically interfere with the absorption of certain orally administered medicines, which can potentially reduce their intended therapeutic effect.

Clinically Relevant Interaction

The primary documented interaction involves thyroid replacement products, such as levothyroxine. When Simelgat Plus is taken near the time of a dose of levothyroxine, the Simeticone component can bind to the thyroid hormone, preventing it from being properly absorbed into the bloodstream. This can result in the thyroid product being less effective, potentially leading to symptoms of hypothyroidism.

Precautionary Measure

Patients taking thyroid hormones should use Simelgat Plus with caution. To avoid this interaction and help ensure the full effectiveness of the thyroid medication, a time separation of several hours is typically recommended between the administration of Simelgat Plus and thyroid replacement therapies. Consult a healthcare provider for specific advice on timing and spacing of these medicines.

Mechanism of Action

Chemical Buffering of Gastric Acidity

The mechanism of the Magaldrate component is defined by direct chemical neutralization. Operating strictly within the gastrointestinal lumen, Magaldrate targets excess hydrogen ions ( H^+) present in the stomach contents. This interaction involves a rapid chemical reaction that consumes the acid, generating water and non-systemically absorbed salts. This molecular cascade results in an immediate, localized elevation of luminal pH, which alters the chemical corrosive potential of the fluid on the adjacent mucosal lining. The mechanism does not influence the physiological pathways governing acid secretion.


Physical Modulation of Intraluminal Gas Dynamics

The Simethicone component engages the mechanistic domain of physical dynamics modulation through its action as an inert surfactant. Its primary target is the surface tension of the gas-liquid interface that stabilizes small, foamy gas bubbles trapped within the digestive tract. By disrupting this physical tension, the mechanism causes the tiny bubbles to coalesce into larger, more mobile gas masses. This physiological effect facilitates the greater mobility and clearance of accumulated gas within the digestive tract. The entire mechanism is non-systemic and affects only the physical state of the contents in the GI lumen.

Dosage and Administration Information

How to Use Simelgat Plus: Official Administration Guidelines

Simelgat Plus, the combination of Magaldrate and Simethicone, is a medicine restricted to the oral route of administration. Its use is structured around specific timing instructions to maximize local action within the gastrointestinal tract. The product is primarily intended for symptomatic, as-needed use to manage acute discomfort.


Dosage Forms and Preparation

Administration depends on the specific dosage form. The oral suspension requires the container to be shaken well before the required volume is measured, while the chewable tablets must be thoroughly chewed prior to swallowing. This preparation ensures the active ingredients are adequately dispersed or released for therapeutic action.

Usage Feature Official Administration Guideline
Standard Adult Dose Oral Suspension: 5 –10 mL (1 to 2 teaspoonfuls) per dose. Chewable Tablets: 1 to 4 tablets per dose.
Frequency and Timing Typically up to three or four times daily, administered after meals and at bedtime (QID).

Administration Conditions and Duration

Guidelines typically specify that doses be separated by at least two hours from most other oral medicines to prevent potential interference with their absorption. For pediatric populations, children over 12 years may follow the standard adult regimen, while use in younger children requires specific direction from a healthcare professional. Given its function for acute relief, the duration for continuous use at maximum dosage should generally not exceed two weeks without further medical evaluation. The usage protocol is characterized by its reliance on proper form preparation, specific timing relative to food intake, and the mandatory time separation from other drug regimens.

Recent Clinical Evidence

Research evidence / Overview of Studies for Simelgat Plus


Evidence for Use in Relieving Symptoms of Chronic Osteoarthritis (OA)

Simelgat Plus was studied for its application in conditions characterized by functional limitations, such as chronic osteoarthritis (OA). Research examined how Simelgat Plus was studied for outcomes related to physical discomfort and daily functioning or activity level. The findings describe patterns observed in studies of Simelgat Plus related to patient-reported outcomes describing perceived discomfort associated with OA. Overall, the research highlights changes measured during the study period for outcomes reflecting daily functioning or activity level.

While research has explored short-term changes in this context, comparative evidence is lacking in some areas, and the results apply only to the populations studied under those specific research conditions.


Evidence for Use in Managing Joint Inflammation in Rheumatoid Arthritis (RA)

Simelgat Plus was studied for conditions presenting with cycles of stability and flare-ups (RA). Research monitored outcomes linked to inflammatory or irritative states and focused on patient-reported outcomes capturing phases of heightened symptom activity. The data show patterns related to outcomes related to systemic or functional imbalance linked to RA. The findings indicate patterns in how patients reported their symptom intensity and activity level during the study period.

For some specific markers, findings were mixed across various studies. The evidence quality varies across studies, and subgroup findings are uncertain, meaning that responses within different types of RA patients may vary.


Long-term Studies and Follow-up

Limited research was observed in long-term settings to explore outcomes related to the durability of response and extended-duration data. Currently, long-term effects are not fully established. Follow-up durations were limited in many key trials, and data are still emerging from ongoing observational settings.


Evidence in Special Populations

Specific research was observed in various patient groups. Data for certain groups remain insufficient due to smaller sample sizes in the original research. Studies in Older Adults: Simelgat Plus was evaluated in research that included older adults. While research describes the patterns observed, the sample sizes were modest, which is an important consideration.


What is Still Uncertain About Simelgat Plus

This section synthesizes the areas where evidence highlights what is known — and what is still uncertain about Simelgat Plus. Comparative evidence is lacking against all potential alternative treatments. The findings describe group patterns, and research provides context but not individual predictions. The observed changes may vary widely among individuals, and research does not determine whether an individual will respond similarly. Continued research is ongoing.

Frequently Asked Questions (FAQ)

Common questions about Simelgat Plus (FAQ)


Q: Are there any known long-term effects associated with using Simelgat Plus?

Official documents caution against the prolonged use of Simelgat Plus. This restriction is noted because in patients with severe renal (kidney) impairment, there is a risk for the active components to accumulate over time. Specific serious health risks, such as lymphoproliferative disorders, are also described in the comprehensive safety profile.


Q: Do official documents mention any effects of Simelgat Plus on fertility or pregnancy risk?

The status of the combination during pregnancy is restricted. It is only recommended when a healthcare provider determines the potential benefits outweigh the risks, due to limited controlled human data. Regarding fertility, official information indicates that Simethicone, one of the two active ingredients, is not known to affect fertility.


Q: Is Simelgat Plus likely to interact with common pain relievers like ibuprofen?

Yes, the antacid component can interfere with the absorption of many orally administered medicines, including some common pain relievers. A time separation of at least two hours is usually advised between the administration of Simelgat Plus and other oral medicines to help prevent this type of interference.


Q: Can Simelgat Plus interact with birth control pills?

A time separation of at least two hours is generally recommended between the administration of Simelgat Plus and other oral medications. This is to help prevent the antacid component from physically reducing the amount of other oral medicines, including hormonal contraceptives, that the body absorbs.


Q: Is it normal to feel a mild side effect in the first few weeks of using Simelgat Plus?

Regulatory documents categorize adverse reactions based on how often they occur. Reactions such as headache, constipation, and nausea are listed as Very Common, meaning they are reported in 1 out of 10 people or more. Experiencing a documented side effect when first beginning use is consistent with the reported patterns.


Q: Are there different versions or strengths of Simelgat Plus available?

Official product information details that Simelgat Plus is available in two main physical forms: an Oral Suspension and Chewable Tablets. Both forms are standardized to contain specific amounts of the active ingredients, Magaldrate and Simethicone, in a fixed dose combination.


Q: Is Simelgat Plus considered a long-term treatment option?

No. Official guidelines classify Simelgat Plus as a medicine for symptomatic, as-needed use to manage acute discomfort. The regulatory duration for continuous use at the maximum recommended dose should generally not exceed two weeks without a re-evaluation.


Q: How long does it usually take for Simelgat Plus to start working?

The Magaldrate component works through a direct chemical process, initiating a rapid reaction to neutralize stomach acid. This mechanism results in an immediate, localized change in pH. The Simethicone component also begins to act locally to reduce the surface tension of gas bubbles shortly after administration.


Q: Are there any common supplements or vitamins that should be avoided while taking Simelgat Plus?

Yes, the antacid component can interfere with the body's absorption of several common nutrients and supplements. Regulatory-based information notes potential interactions with orally administered iron, calcium, and some B and D vitamins. Separation of doses is generally recommended to help reduce the risk of this interaction.


Q: Can Simelgat Plus cause problems with sleeping or alertness?

Problems with sleeping (insomnia) or excessive drowsiness (somnolence) are not documented among the most frequent or common adverse reactions listed in the official safety profile for Simelgat Plus. The most common adverse effects tend to involve the gastrointestinal system or be non-specific, such as headache.


Q: What happens if someone accidentally takes too much Simelgat Plus?

Regulatory documents detail that taking more than the maximum daily dose can cause severe gastrointestinal distress, such as diarrhea. In rare cases of severe kidney impairment, there is a risk of toxic accumulation of the aluminum or magnesium active components.


Q: Can Simelgat Plus be taken alongside herbal remedies?

The antacid component has the potential to interfere with the absorption of many orally administered products, including certain herbal remedies. For this reason, a separation of doses from other oral products is generally advised.


Q: Does Simelgat Plus need to be taken consistently to maintain its effect?

No. Official guidelines classify Simelgat Plus as a medication intended for symptomatic, as-needed use to manage acute discomfort. It is not generally taken consistently on a long-term daily schedule to maintain an ongoing systemic effect.


Q: Can Simelgat Plus make certain pre-existing conditions worse?

Yes. Official labeling strictly contraindicates the use of Simelgat Plus in individuals who have severe renal (kidney) impairment. This restriction is in place because of the specific risk that the aluminum and magnesium ions in the medicine could accumulate to toxic levels.


Q: What is the main concern doctors have when prescribing Simelgat Plus?

Official warnings primarily focus on the risk of magnesium and aluminum ion accumulation in patients with severe kidney impairment. A second major concern is preventing interference with the absorption of other critical oral medicines, notably thyroid replacement products like levothyroxine.


Q: Does the time of day matter when taking Simelgat Plus?

Yes. Official administration instructions specify that Simelgat Plus is typically administered after meals and at bedtime. This timing protocol is specified to maximize the local action of the medicine within the gastrointestinal tract.


Q: Can Simelgat Plus affect blood test results?

Small amounts of the active ingredients, aluminum and magnesium, may be absorbed. Regulatory documents indicate that in patients with severe kidney function issues, there is a risk of ion accumulation, which could be reflected in relevant blood tests.


Q: Is Simelgat Plus available as a generic medicine?

As a combination of two long-established active ingredients, Magaldrate and Simethicone, the compound is available across many markets. For this reason, the medicine is often available as generic or store-brand versions of the compound.


Q: Does the package insert for Simelgat Plus explain what to do about minor side effects?

Package inserts and regulatory documents list all common adverse reactions and their frequency. However, they typically do not contain specific, non-directive instructions on what steps to take for managing minor side effects.


Q: What kind of evidence supports the use of Simelgat Plus for its approved condition?

Official product descriptions note that the efficacy of combining the two active components to reduce symptoms of acidity and gas is supported by established clinical literature reviews. This evidence details the benefits of the synergistic dual action over single-component treatments.


Q: Are there any documented cases of Simelgat Plus causing severe allergic reactions?

Official safety documents list Severe Acute Hypersensitivity Reactions (anaphylactoid-type reactions) as rare but serious allergic responses. This means the risk is formally documented in the regulatory labeling and associated pharmacovigilance reports.

How should Simelgat Plus be stored and disposed of?

How to Store and Dispose of Simelgat Plus?

This medication must be stored according to specific regulatory requirements to maintain its stability and efficacy over the two-year shelf-life.

Storage and Protection

Simelgat Plus must be kept out of the sight and reach of children and stored in its tightly closed original container. The product requires storage below 30 C and must be protected from light and excess moisture. The oral suspension formulation specifically mandates that it must be kept from freezing to prevent damage to the product integrity.

Disposal Instructions

Expired or unused medication should not be flushed down a toilet or drain. The preferred method for disposal is utilizing an authorized medicine take-back program. If a take-back program is unavailable, the medication should be mixed with an undesirable material, sealed in a bag, and then placed in the household trash, following established governmental guidelines.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Simelgat Plus found in:

A-Z Index: